Get With The Guidelines® - 360° Improvement Measures

How Achievement And Quality Measures Are Determined

Achievement and quality measures provide the basis for evaluating and improving treatment of Heart Failure patients. Formulating those measures begins with a detailed review of HF guidelines. When evidence for a process or aspect of care is so strong that failure to act on it reduces the likelihood of an optimal patient outcome, an achievement measure may be developed regarding that process or aspect of care. Achievement measure data are continually collected, and results are monitored over time to determine when new initiatives or revised processes should be incorporated. As such, achievement measures help speed the translation of strong clinical evidence into practice. In order for participating hospitals to earn recognition for their achievement in the program, they must adhere to achievement measures. Quality measures apply to processes and aspects of care that are strongly supported by science. Application of quality measures may not, however, be as universally indicated as achievement measures. The Get With The Guidelines team follows a strict set of criteria in creating achievement and quality measures. We make every effort to ensure compatibility with existing performance measures from other organizations.

Get With The Guidelines® – 360°  Initiative Improvement Measures

  • Follow-up visit within 7 days or less
    Percent of eligible heart failure patients who underwent a follow-up visit within 7 days or less from time of hospital discharge.
  • Heart failure disease management program referral
    Percent of heart failure patients referred to disease management program.
  • Influenza vaccination during flu season
    Percent of patients that received an influenza vaccination prior to discharge during flu season.
  • Aldosterone antagonist at discharge
    Percent of heart failure patients with left ventricular systolic dysfunction (LVSD) with no contraindications or documented intolerance who were prescribed aldosterone antagonist at discharge.
  • 30 Day ACEI/ARBs or ARNi
    Percent of heart failure patients with left ventricular systolic dysfunction (LVSD) and without ACEI/ARBs or ARNi contraindications who are on ACEI/ARBs or ARNi 30 days post discharge.
  • 30 Day Beta-Blocker for LSVD
    Percent of heart failure patients on Beta-Blocker 30 days post discharge.
  • 30 Day rehab/disease management
    Percent of heart failure patients who have received cardiac rehab or disease management within 30 days of discharge.

Novartis

The American Heart Association/American Stroke Association thanks Novartis for its support of the Quality Improvement Platform

Novartis